Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.

Deb Gokie discusses the Arthritis Foundation's inclusive design program, emphasizing its impact on medical device and ...

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

Stock market sell-offs are often great opportunities to buy dividend stocks. That's because dividend yields move in the ...

AbbVie Inc. stands out as one of the top pharma stocks to buy, according to hedge funds. The company exceeded analyst ...

Researchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...